CBIS initiates CS-TATI-1 GMP development plan Cannabis Technology , a pioneering U.S. Biotech Organization developing pharmaceutical to meet up global public health challenges is pleased to announce the initiation of GMP advancement arrange for CS-TATI-1 with the original production of CS-TATI-1 to become performed in Colorado under C-GMP conditions evaluated by the FDA for initial human studies to take care of HIV linked Kaposi Sarcoma http://www.propeciasverige.com read more . The codependent relation of the TAT’s expression at the HIV LTR and the upregulation of Nf-KB dependent expression of Kaposi Sarcoma is well defined in peer examined publications.


Related StoriesNew RNA test of bloodstream platelets may be used to identify location of cancerCornell biomedical engineers develop 'super natural killer cells' to destroy tumor cells in lymph nodesMD Anderson study reveals why chemotherapy drugs not effective for most pancreatic tumor patientsSara B. Capitelli, CASI's Vice President, Financing, commented on the second quarter results, Our second quarter 2015 financial results were consistent with expectations. Study and development expenses increased compared with the prior year primarily because of higher clinical trial costs associated with our food effect study of ENMD-2076 in healthy human subjects, an increase in patient enrollment on other clinical trials, in addition to increased costs connected with our analysis and development procedures in China during 2015.